SCHEMBL5841563

SCHEMBL5841563

Cc1cccc(OB(O)c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.47
LMNA P02545 2/20 0.44
ENPP2 Q13822 1/20 0.42
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
PPARG P37231 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RECQL P46063 1/20 0.39
HTT P42858 2/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP26B1 Q9NR63 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5156121 0.85 NPSR1 (0.39) ENPP2ALDH1A1SMN1; SMN2MAPTCYP26B1
SCHEMBL6610175 0.81 ACHE (0.50) ACHELMNAALDH1A1GAADRD2
SCHEMBL2475622 0.80 ORAI1 (0.48) LMNAENPP2ALDH1A1RECQLCYP26B1
SCHEMBL6379719 0.80 ENPP2 (0.48) LMNAENPP2ALDH1A1DRD2DRD4
SCHEMBL29133596 0.79 CA2 (0.46) ACHELMNAENPP2DRD2DRD4
SCHEMBL2474216 0.79 ACHE (0.43) ACHELMNAENPP2DRD2DRD4
SCHEMBL29435910 0.79 ACHE (0.56) ACHELMNAENPP2ALDH1A1GAA
SCHEMBL557190 0.79 ACHE (0.56) ACHELMNAENPP2ALDH1A1GAA
SCHEMBL29125537 0.79 MAOB (0.53) LMNAENPP2ALDH1A1GAAMEN1
Anthracene SCHEMBL5574730 0.77 CA1 (0.42) ENPP2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115959993-B Synthesis method of 2-aryl propionic acid compound 山东中医药大学 2025-01-07 CN claimed
CN-111303150-A High-efficiency narrow-half-peak-width aggregation state luminescent material 苏州大学 2020-06-19 CN claimed
CN-114262330-B Fascaplysin derivative, preparation method and application thereof in resisting MRSA 宁波大学 2023-12-12 CN disclosed
CN-111303150-B High-efficiency narrow-half-peak-width aggregation state luminescent material 苏州大学 2021-10-19 CN disclosed
CN-111303150-A High-efficiency narrow-half-peak-width aggregation state luminescent material 苏州大学 2020-06-19 CN disclosed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ACHE 1244/4885LMNA 4410/4885ENPP2 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.